Bruce D. Walker

American physician

Bruce D. Walker

Born| 04/18/1952
Nationality| American
Education| University of Colorado, Boulder

Case Western Reserve University

Mass General Hospital

Harvard Medical School
Occupation(s)| Physician and scientist

HIV/AIDS researcher

Board-certified in internal medicine and infectious disease

Director, Ragon Institute of Mass General, MIT, and Harvard

Principal investigator, Ragon Institute
Known for| Ranked No. 18 globally and No. 15 nationally among Research.com’s top immunologists

Elected member, National Academy of Medicine

2 NIH Merit Awards recipient

Described HIV-specific CD8+ T cells and HIV-specific CD4+ T cells

Defined the role of HIV-specific T cells in acute and chronic HIV infection and transmission

Discovered the role of immune checkpoints in dysfunctional cellular immune responses to HIV

Characterized both host and viral genetic factors involved in modulating HIV disease

Establishment of Ragon Institute

Founding co-director of the Africa Health Research Institute (formerly KwaZulu Natal Research Institute for TB and HIV)

Founding co-faculty director, Massachusetts Consortium on Pathogen Readiness (MassCPR)
Website| https://ragoninstitute.org/walker/

Bruce D. Walker is an American physician and scientist whose infectious disease research has produced many findings regarding HIV/AIDS.[1] He became interested in studying HIV/AIDS after practicing on the front lines of the epidemic in the early 1980s, prior to the identification of HIV as the etiologic agent and prior to the availability of viable treatment options.[2]

An infectious disease specialist and researcher, Walker is the founding director of the Ragon Institute of Mass General, MIT, and Harvard.[1] He is also an investigator at Howard Hughes Medical Institute, an adjunct professor at Nelson R. Mandela School of Medicine at the University of KwaZulu-Natal, and a founding co-director of the Africa Health Research Institute, formerly known as KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH).[3]

He played an active role in COVID-19 research, helping found and co-lead the Massachusetts Consortium on Pathogen Readiness (MassCPR) and advance vaccine development with the Ragon Institute.[4][5]

Walker was named a Fellow of the American Association for the Advancement of Science in 2004.[6] He was elected to the National Academy of Medicine in 2009.[7]

## Early life and education[edit]

After graduating from high school, Walker worked as a roofer. He had grown up assuming he would eventually become a scientist and subsequently obtained a bachelor's of science degree in chemistry from the University of Colorado, Boulder.[8] He went on to receive a medical degree from Case Western Reserve University, where he was drawn to clinical medicine. He completed his internship and residency in internal medicine at Mass General Hospital and Harvard Medical School from 1980 to 1983, followed by an internship pathology and fellowship training in infectious disease.[9] He is board certified in both internal medicine and infectious disease.[10]

In 1980, as an intern at Mass General Hospital working on the front lines of the still-unidentified HIV/AIDS epidemic, Walker encountered a young man who was admitted to the hospital with multiple simultaneous infections and cancers. This proved to be a sentinel case of a new disease called AIDS, the cause of which was unknown and for which no specific treatment was available.[2][11]

By the time HIV was identified as the cause of AIDS, Walker and his colleagues had seen many patients with advanced HIV/AIDS, for which few treatment options existed. He has described these experiences as "excruciating" and "heartbreaking." They led Walker to specialize in infectious disease and begin researching HIV in the laboratory, to understand how the body fought back and why it often lost the battle.[2][12]

## Career[edit]

Walker is considered a world leader in research surrounding immune control and immune evasion in HIV infection.[9][13]

### Research into T cell responses and "elite controllers"[edit]

In 1987, Walker became among the first researchers, together with his mentors Robert Schooley and Martin Hirsch, to describe HIV-specific CD8+ T cells.[12][14] Studying persons with HIV infection with grant support from the American Cancer Society, Walker identified extremely robust responses in persons with advanced disease, using recombinant vaccinia viruses to express HIV proteins.[14][15]

Before effective antiretroviral therapy was available, Walker met a patient with hemophilia who had been infected with HIV through a blood product in 1978 but never developed AIDS. At first, Walker did not believe the patient had HIV because he had remained healthy despite being infected for 17 years, as confirmed by the patient's years of stored blood samples. This experience initiated a career of learning from patients, inspiring subsequent research into "elite controllers," the less than 1 percent of people living with HIV who remain healthy, without medication, decades after infection.[16] Studying these individuals has been a major focus of Walker's research efforts, leading to the discovery of HIV-specific CD4+ T cells.[17]

In South Africa, Walker has worked with Drs. Krista Dong, Thumbi Ndung'u, and collaborators to focus on hyperacute HIV infection. They perform their work through a cohort called FRESH, meaning, "Females Rising through Education, Support, and Health." FRESH is a program that combines HIV prevention, a pathway out of poverty for young women at high risk, and a study of hyperacute HIV infection.[18][19]

One goal of the program is to ward off HIV infections through a prevention curriculum that includes life skills training, empowerment skills, computer education, HIV prevention education, PrEP (pre-exposure prophylaxis), and job readiness training. Organizers aspire to help participants find employment after nine months in the program. The second goal is to identify persons in the window period before peak viremia and seroconversion (defined by Fiebig Stages I-VI), to determine how the battle between host and virus begins.[18][19] Through this study, Walker and colleagues have determined that the higher initial magnitude of the HIV-specific T cell response, the lower the viral set point in untreated infection.[20] They also found that immediate treatment leads to more functional immune responses.[21]

### Doris Duke Medical Research Institute (DDMRI) and the Africa Health Research Institute[edit]

In 1998, Walker began research in KwaZulu-Natal (KZN) province, South Africa. The initial plan had been to find collaborators in South Africa, hardest hit by the AIDS epidemic, to study immune responses in babies born with HIV infection, who typically have very rapid disease progression. The stated goal was to bring samples back to the US, but the African collaborators, led by the late Hoosen (Jerry) Coovadia, asked Walker and colleagues to consider doing the studies in Durban and teach them to conduct fundamental research. This prompted the establishment of a small laboratory at the University of KwaZulu Natal (UKZN) in Durban.[22]

Recognizing the wealth of knowledge that could be gained by conducting research at the heart of the TB and HIV epidemics, as well as the need for capacity building for fundamental and translational research,[23] Walker, Coovadia, Salim Abdool Karim, and Philip Goulder initiated a plan to build a research laboratory at the University, which had not had a new building built in over 50 years. In 2003, the Doris Duke Medical Research Institute (DDMRI) opened at the Nelson R. Mandela School of Medicine. The institute was largely funded through a Doris Duke Charitable Foundation Walker had received at MGH. UKZN took ownership of the new facility.[24]

In 2012, the research facilities there were expanded to include the KwaZulu-Natal Research Institute for TB and HIV (K-RITH), funded by Walker’s employer the Howard Hughes Medical Institute and for which Walker served as a founding co-director.[25] K-RITH has subsequently been renamed the Africa Health Research Institute.[26]

### Ragon Institute of Mass General, MIT, and Harvard[edit]

The Ragon Institute of Mass General, MIT, and Harvard was officially established in 2009, with the support of Phillip Ragon and his wife, Susan M. Ragon. Walker met Phillip Ragon at the request of a salesman for an electronic medical record (EMR) being used at a mission hospital where Walker and collaborators were working to treat persons living with HIV. Ragon’s company, InterSystems, had just acquired the EMR, and the salesman wanted Walker to convey how important the EMR was for treatment of persons living with HIV. This led to a brief conversation between Walker and Ragon, followed by a short trip to KZN to see the EMR in action and to get a view of the ongoing HIV epidemic. After three days, Ragon asked how he could help. In the end, he and Susan Ragon donated $100 million in 2009 to establish the Ragon Institute, whose vision is to harness the immune system to prevent and cure human disease. The foundations of the Institute began with HIV research in South Africa,[27] and HIV remains one of the institute’s primary areas of focus.[28] During the organization’s first two years, Walker brought on 40 new scientists to research HIV.[22] Walker works as a principal investigator at the Ragon Institute and focuses with his team on the body’s immune response to viral infection,[1] including through studies of patients with chronic HIV infection and those who can control HIV infection to undetectable levels without the need for antiretroviral therapy (ART).[16][29]

### Research work and career highlights[edit]

* Professor of Medicine, Harvard Medical School.[30]
* Professor of the Practice, Institute for Medical Engineering and Science and Department of Biology, MIT.[31]
* Adjunct Professor of Medicine, Nelson Mandela School of Medicine, University of KwaZulu-Natal.[30]
* Investigator, Howard Hughes Medical Institute.[27]
* Faculty Co-leader, Massachusetts Consortium on Pathogen Readiness (MassCPR), a group of collaborators aiming to address the challenges faced during COVID-19 and to enhance precautions for future pandemics.[32]
* Scientific collaboration in South Africa, leading to the establishment of the Doris Duke Medical Research Institute and the Africa Health Research Institute.[24]
* Established the FRESH program, merging the study of the immune system's response to HIV with a social program.[18][19]
* Established the MIT course "Evolution of an Epidemic," bringing undergraduate students to South Africa.[33]
* First to describe HIV-specific CD8+ T cells and HIV-specific CD4+ T-cell responses.[12]
* Defined the role of T cells in acute and chronic HIV infection and transmission.[1]
* Discovered the role of immune checkpoints in dysfunctional cellular immune responses to HIV.[1]
* Characterized both hosts and viral genetic factors involved in modulating viral control.[1]
* Played an active role in COVID-19 research and vaccine development with the Ragon Institute.[4][5]
* Holds an honorary doctorate of science degree from Case Western Reserve University for his accomplishments in HIV/AIDS research and work with the Ragon Institute.[34]

## Awards and recognition[edit]

The following are awards and honors bestowed upon Walker:

* Ranked No. 18 on Research.com's list of the world's top immunologists.[13]
* Recipient of two NIH Merit Awards, in 1994 and 2011.[35]
* Recipient of Doris Duke Charitable Foundation Distinguished Clinical Scientist Award.[35]
* Elected member of the National Academy of Medicine and the American Academy of Arts and Sciences.[36][37]
* Recipient of the Barcelona AIDS Award (Fight Against AIDS Foundation) and Heroes in Action Award (AIDS Action Committee).[38][39]

## References[edit]

Scholia has a profile for Bruce D. Walker (Q23770361).

1. ^ a b c d e f "Walker - Ragon Institute of Mass General, MIT, and Harvard". Walker. Retrieved 2023-11-06.
2. ^ a b c Neel, Dylan (2023-02-07). "Lab Meeting: Bruce Walker". Biomarker. Retrieved 2023-11-06.
3. ^ "Bruce D. Walker, MD | Investigator Profile | 2002-Present | HHMI". www.hhmi.org. Retrieved 2023-11-06.
4. ^ a b Couzin-Frankel, Jennifer (March 5, 2020). "With $115 million, more than 80 Boston researchers will collaborate to tackle COVID-19". Science. Retrieved November 6, 2023.
5. ^ a b Narayanan, Srinidhi (April 15, 2021). "MIT hosts COVID-19 vaccine webinar with Harvard and Ragon Institute". The Tech. Retrieved 2023-11-06.
6. ^ "Faculty, alumni named AAAS fellows". Case Western Reserve University. November 15, 2004. Retrieved March 13, 2016.
7. ^ "Bruce D. Walker, M.D." National Academy of Medicine. Retrieved March 13, 2016.[permanent dead link]
8. ^ "The Realm of Possibility | Understanding How the Body Fights HIV Infection". Retrieved 2023-11-08.
9. ^ a b "Bruce Walker, MD". CHAVD. Retrieved November 8, 2023.
10. ^ "Dr. Bruce D. Walker". U.S. News & World Report. Retrieved November 8, 2023.
11. ^ "The AIDS Epidemic in the United States, 1981-early 1990s | David J. Sencer CDC Museum | CDC". www.cdc.gov. 2021-04-29. Retrieved 2023-11-08.
12. ^ a b c Archives, L. A. Times (1987-07-23). "Cell That Destroys AIDS Virus Discovered". Los Angeles Times. Retrieved 2023-11-08.
13. ^ a b "Bruce D. Walker". Research.com. Retrieved November 14, 2023.
14. ^ a b Walker, Bruce D.; Chakrabarti, Sekhar; Moss, Bernard; Paradis, Timothy J.; Flynn, Theresa; Durno, Amy G.; Blumberg, Richard S.; Kaplan, Joan C.; Hirsch, Martin S.; Schooley, Robert T. (July 1987). "HIV-specific cytotoxic T lymphocytes in seropositive individuals". Nature. 328 (6128): 345–348. Bibcode:1987Natur.328..345W. doi:10.1038/328345a0. ISSN 1476-4687. S2CID 4238505.
15. ^ Walker, Bruce D.; Flexner, Charles; Paradis, Timothy J.; Fuller, Thomas C.; Hirsch, Martin S.; Schooley, Robert T.; Moss, Bernard (April 1988). "HIV-1 Reverse Transcriptase Is a Target for Cytotoxic T Lymphocytes in Infected Individuals". Science. 240 (4848): 64–66. Bibcode:1988Sci...240...64W. doi:10.1126/science.2451288. ISSN 0036-8075. PMID 2451288.
16. ^ a b Shaw, Jonathan (January 2019). "People Who Don't Get AIDS". Harvard Magazine. Retrieved November 14, 2023.
17. ^ "Special Type of Immune Cell May Be Key to Avoiding AIDS". The New York Times. November 21, 1997. pp. Section A, Page 18. Retrieved November 14, 2023.
18. ^ a b c Ndung’u, Thumbi; Dong, Krista L.; Kwon, Douglas S.; Walker, Bruce D. (2018-09-21). "A FRESH approach: Combining basic science and social good". Science Immunology. 3 (27). doi:10.1126/sciimmunol.aau2798. ISSN 2470-9468. PMC 7593829. PMID 30217812.
19. ^ a b c Parsons, Lian (2019-09-19). "Ragon Institute receives major gift to expand research into autoimmune diseases". Harvard Gazette. Retrieved 2023-11-14.
20. ^ Ndhlovu, Zaza; Kamya, Philomena; Dong, Krista; Ndung'u, Thumbi; Walker, Bruce (September 15, 2015). "Magnitude and Kinetics of CD8+ T Cell Activation during Hyperacute HIV Infection Impact Viral Set Point". Immunity. 43 (3): 591–604. doi:10.1016/j.immuni.2015.08.012.
21. ^ Ndhlovu, Zaza M.; Kazer, Samuel W.; Nkosi, Thandeka; Ogunshola, Funsho; Muema, Daniel M.; Anmole, Gursev; Swann, Shayda A.; Moodley, Amber; Dong, Krista; Reddy, Tarylee; Brockman, Mark A.; Shalek, Alex K.; Ndung’u, Thumbi; Walker, Bruce D. (2019-05-22). "Augmentation of HIV-specific T cell function by immediate treatment of hyperacute HIV-1 infection". Science Translational Medicine. 11 (493). doi:10.1126/scitranslmed.aau0528. ISSN 1946-6234. PMC 6901350. PMID 31118290.
22. ^ a b Kresge, Kristen Jill; McEnery, Regina (July–August 2011). "The House that Bruce Built" (PDF). IAVIReport. pp. 4–11. Retrieved November 19, 2023.
23. ^ Goulder, P. J.; Brander, C.; Tang, Y.; Tremblay, C.; Colbert, R. A.; Addo, M. M.; Rosenberg, E. S.; Nguyen, T.; Allen, R.; Trocha, A.; Altfeld, M.; He, S.; Bunce, M.; Funkhouser, R.; Pelton, S. I. (2001-07-19). "Evolution and transmission of stable CTL escape mutations in HIV infection". Nature. 412 (6844): 334–338. doi:10.1038/35085576. ISSN 0028-0836. PMID 11460164. S2CID 4332431.
24. ^ a b Lok, Corie (May 26, 2011). "His Best Shot: Can Bruce Walker transform HIV vaccine research?" (PDF). Nature. 473: 439–441. doi:10.1038/473439a. PMID 21614054.
25. ^ "K-RITH Brings Exceptional TB and HIV Research Capabilities to Durban and the World | HHMI". www.hhmi.org. Retrieved 2023-11-19.
26. ^ Pillay, Deenan (2016-07-18). "Scientists are combining forces to tackle the deadly duo of TB and HIV". The Conversation. Retrieved 2023-11-19.
27. ^ a b www.bizjournals.com https://www.bizjournals.com/boston/news/2019/04/29/heres-how-a-chance-visit-led-to-the-largest.html. Retrieved 2023-11-19. `{{cite web}}`: Missing or empty `|title=` (help)
28. ^ Rosado, Gloria (2020-07-28). "Five Things to Know About the Ragon Institute". Bench Press. Retrieved 2023-11-19.
29. ^ O'Sullivan, Dan (June 4, 2019). "Ragon Institute: Harnessing the Power of Human Immunity". Massachusetts General Hospital.
30. ^ a b "Bruce David Walker". dms.hms.harvard.edu. Retrieved 2023-11-19.
31. ^ "Bruce Walker". MIT Department of Biology. Retrieved 2023-11-19.
32. ^ "About Us". masscpr.hms.harvard.edu. Retrieved 2023-11-19.
33. ^ "New HST.S46 IAP course "Evolution of an Epidemic" takes MIT undergrads to the heart of the AIDS epidemic in Africa". Harvard-MIT Health Sciences and Technology. 2017-03-27. Retrieved 2023-11-19.
34. ^ Smith, Brianna (2023-05-16). "Celebrating our graduates: Commencement events to be held throughout the week for the Class of 2023". The Daily. Retrieved 2023-11-19.
35. ^ a b "Bruce Walker". Institute for Medical Engineering & Science. 2022-08-29. Retrieved 2023-11-19.
36. ^ "Dr. Bruce D. Walker". National Academy of Medicine.
37. ^ "Bruce D. Walker". American Academy of Arts & Sciences. 2023-10-18. Retrieved 2023-11-19.
38. ^ "AID FOR AIDS International - My Hero Gala". Musée Magazine. 2012-11-12. Retrieved 2023-11-19.
39. ^ Times, The Rainbow (2017-06-06). "AIDS Walk & Run Boston Raises $750,000 to Support Work to End HIV/AIDS in MA". The Rainbow Times | New England's Largest LGBTQ Newspaper | Boston. Retrieved 2023-11-19.